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ABSTRACT
The term ‘extended-spectrum b-lactamase’ (ESBL), initially ‘extended-broad-spectrum b-lactamase’, was
ﬁrst coined for derivatives of TEM and SHV enzymes able to hydrolyse oxyimino-cephalosporins. These
all belonged to b-lactamase functional group 2be. Subsequently, the term has been stretched to include:
(i) enzymes with spectra similar to those of TEM and SHV mutants but derived from other sources, e.g.,
the CTX-M and VEB types; (ii) TEM and SHV mutants with borderline ESBL activity, e.g., TEM-12; and
(iii) various b-lactamases conferring wider resistance than their parent types but not meeting the
deﬁnition for group 2be, e.g., OXA derivatives and mutant AmpC types with increased activity against
cefepime. It seems best—and pragmatic—that the term ‘ESBL’ retains its broad modern usage, but that
should always be accompanied by mention of the enzyme’s family as, e.g., in ‘TEM ESBL’ or ‘OXA
ESBL’, not as a sole moniker.
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THE BEGINNINGS OF A TERM
The development of broad-spectrum penicillins in
the 1960s was swiftly followed by the emergence
of resistance and by recognition that most of this
resistance was due to b-lactamases. Multiple
b-lactamase types were recognised and a classiﬁ-
cation was developed by Richmond and Sykes [1],
based on hydrolytic proﬁles, susceptibility to
inhibition by p-chloromercuri-benzoate and clox-
acillin, and whether the enzymes were plasmid-
mediated or chromosomal. Hydrolytic proﬁle was
based on relative activity against cephaloridine
and benzylpenicillin and was deﬁned as ‘cepha-
losporinase’, ‘penicillinase’, or ‘broad spectrum’,
when both reference substrates were hydrolysed
at similar rates. Among the broad-spectrum
enzymes, placed in group III, were the TEM-1,
TEM-2 and SHV-1 types, which rapidly became
the major sources of acquired resistance to the
broad-spectrum penicillins [2]. TEM-1 had
already spread to 30–50% of Escherichia coli
isolates and was well-established in other Entero-
bacteriaceae by the early 1970s; by the mid-1970s,
it had spread also to Haemophilus inﬂuenzae and
Neisseria gonorrhoeae. TEM-2 and SHV-1 enzymes
remained ten-fold less prevalent than TEM-1 but
also became widely scattered, generally scoring as
the second and third most prevalent b-lactamases
in surveys undertaken in the 1970s and early
1980s [3]. The origins of the TEM types remain
uncertain, but SHV-1 was later realised to be
derived from the chromosomal b-lactamase of
Klebsiella pneumoniae [4].
The spread of plasmid-mediated TEM and SHV
enzymes provided a major impetus for the devel-
opment of ‘b-lactamase-stable b-lactams’ from the
mid-1970s onwards. These included oxyimino-
cephalosporins (Fig. 1), cephamycins, temocillin,
aztreonam and carbapenems. For reasons of
convenience, spectrum, cost and safety, the oxyi-
mino-cephalosporins—principally cefuroxime,
cefotaxime, ceftriaxone, ceftazidime and cefe-
pime—became the most-used of these analogues,
and are now standard therapies for pneumonias,
intra-abdominal infections, and urinary infection
in many hospitals worldwide. Ceftriaxone was
the ﬁrst injectible antibiotic to have achieved a
turnover of $1 billion per annum, equating to
about 10% of the global market.
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Needless to say, this heavy usage has exerted
great selection pressure for resistance, which ﬁrst
became a concern in Enterobacter, Citrobacter and
Serratia spp., where it is mostly contingent on
mutational depression of chromosomal AmpC
b-lactamases [5,6]. In 1982, however, Kliebe et al.
[7] described a K. pneumoniae strain fromGermany
with SHV-2 b-lactamase, a mutant of SHV-1
capable of hydrolysing oxyimino-cephalosporins.
Perhaps surprisingly, there were no more such
mutants recorded for 5 years until Sirot et al. [8]
reported an ongoing problem with multiple
enterobacterial species in Clermont-Ferrand
(France) producing a potent cephalosporinase,
which they named CTX-1. Subsequent sequencing
showed that CTX-1 was a three-amino-acid mu-
tant of TEM-1 and it was renamed TEM-3 [9]. By
this time, others, mostly in France, were describing
series of different cefotaximases (CTX) and ceftaz-
idimases (CAZ). These, too, largely proved to be
TEM and SHVmutants and, once sequenced, were
re-numbered within these families. Now, 20 years
on, the catalogues of TEM and SHV variants have
grown to 150 and over 88, respectively (see http://
www.lahey.org/studies for an up-to-date listing),
most of them with increased activity against
oxyimino-cephalosporins.
The term ‘extended-broad-spectrum b-lacta-
mases’ was applied to the oxyimino-cephalo-
sporin-hydrolysing TEM and SHV enzymes in
1987 [10], based on the fact that they had
‘extended broad-spectrum’ activity as compared
with the ‘broad-spectrum’ classic TEM and SHV
enzymes in Richmond and Sykes’ group III. Soon,
however, the word ‘broad’ had been lost from
the moniker and, by 1989, ‘extended-spectrum
b-lactamases’ (ESBLs) was used in a seminal
review [11] and ICAAC abstracts. Karen Bush,
revising the b-lactamase classiﬁcation of Rich-
mond and Sykes in 1989, put ESBLs into her
class 2be (initially 2b¢, renamed 2be in 1995 [12]),
as broad-spectrum clavulanate-inhibited b-lacta-
mases, able to hydrolyse oxyimino-cephalosporin
at rates of at least 10% that for benzylpenicillin
[13]. Class 2be also accommodated the chromo-
somal K1 (KOXY) b-lactamase of Klebsiella oxytoca,
whereas further b-lactamases, able to hydrolyse
oxyimino-cephalosporins and inhibited by clavul-
anate, were placed in group 2e on the basis of
being substantially more active against cephalor-
idine than benzylpenicillin [14].
BLURRING THE EARLY DEFINITIONS
If ESBLs had remained exclusively clavulanate-
inhibited TEM and SHV mutants with substitu-
tive activity against oxyimino-cephalosporins,
their deﬁnition would remain simple. Unfortu-
nately, they have not.
First, other enzymes with similar hydrolytic
proﬁles and inhibitor susceptibility to the TEM
and SHV mutants, but with dissimilar evolution-
ary histories, have been recognised, notably the
CTX-M, PER and VE13 groups. Second, some
TEM mutants have increased cephalosporinase
activity, as compared with TEM-1, and a greater
ability to confer resistance, but fail to meet the
criterion of hydrolysing any individual oxyimino-
cephalosporin at 10% or more of the rate for
benzylpenicillin. Third, mutation can extend the
hydrolytic spectrum and ⁄ or the capacity to cause
resistance among class C and D b-lactamases,
which are inherently resistant to clavulanate and
therefore cannot belong to functional group 2be.
Fourth, some enzymes, particularly in the GES
family, meet the criteria for inclusion in class 2be
but, in addition, slowly hydrolyse carbapenems.
Depending on the author, some or all of these
groups are included as ESBLs. Should they be?
Underlying this confusion is the issue of whether
‘ESBL’ still serves as a descriptor of hydrolytic
activity, as in the original ‘extended-broad-spec-
trum,’ or whether the term has evolved to become
phylogenetic—indicating that an enzyme has an
extended spectrum as compared with classic
members of its family.
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Fig. 1. Structure of an oxyimino-aminothiazolyl cephalo-
sporin. The C=N–OR group, shaded, is held rigid and
shields the b-lactam ring from attack by classic b-lacta-
mases, but not by extended-spectrum b-lactamases. Cef-
uroxime, cefotaxime, ceftriaxone, ceftazidime, cefepime
and cefpirome are all designed on this scaffold.
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CLASS A ENZYMES SIMILAR TO TEM
AND SHV ESBLS , BUT UNRELATED
TO THEM
Several groups of acquired b-lactamases have
hydrolytic proﬁles similar to those of the TEM
and SHV mutants but have quite different evolu-
tionary histories, although they also belong to
molecular class A. Major examples include: (i) the
CTX-M family, rapidly spreading worldwide [15];
(ii) the PER family, important in Pseudomonas,
Acinetobacter and Salmonella in Turkey [16,17] and
in Salmonella in Argentina [18]; (iii) the VEB
family, which is most prevalent in the Far East
[19] but which has also been seen in Western
Europe, most notably in an Acinetobacter bauman-
nii clone that spread widely in north-eastern
France in 2003–2004 [20,21]; and (iv) various rare
types, such as GES and TLE.
These are all acquired, generally plasmid-med-
iated, enzymes, inhibited by clavulanate and able
to hydrolyse one or more oxyimino-cephalospo-
rin(s) at 10% or more of the rate for benzylpen-
icillin, thus meeting the key criteria for inclusion
in functional group 2be. Despite not having par-
ents with narrower spectra, they should surely be
included as ESBLs, as supported both by this
author and by a show of hands at the conference.
What is more arguable is whether one should
also include, as ESBLs, chromosomal types meet-
ing the inhibition and hydrolytic criteria for
group 2be. Enzymes that might be recruited to
the class on this basis include the K. oxytoca
K1 ⁄KOXY b-lactamase, which is placed in func-
tional group 2be, and the Proteus vulgaris, Citrob-
acter diversus and Stenotrophomonas maltophilia L-2
chromosomal enzymes, placed in group 2e [14].
Perhaps most obviously, since the CTX-M family
are genetic escapes from Kluyvera spp., [15]
should not the corresponding chromosomal types
in Kluyvera be counted as ESBLs?
My preference would be to exclude chromo-
somal types and to reserve the term ‘ESBL’ for
acquired types, atypical of their host species,
whether encoded by plasmids or chromosomal
inserts. But this is an issue of preference, and
many who attended the conference took the
opposite view also accepting the term ESBL for
enzymes that were inherent and chromosomal in
a species.
TEM AND SHV MUTANTS WITH
BORDERLINE ESBL ACTIVITY
Most TEM and SHV ESBLs have Vmax rates for
oxyimino-cephalosporins as high as those for
benzylpenicillin or cephaloridine, whereas TEM-
1 has 10 000-fold lower rates (Table 1). However,
a few TEM mutants, e.g., TEM-12, have only
slightly increased activity against the cephalospo-
rins, with Vmax rates much lower than 10% of that
for benzylpenicillin [22]. They therefore fail to
meet the criteria for inclusion in class 2be but
nevertheless, are more active against the oxyimi-
no-cephalosporins than TEM-1 itself, and confer
low-level resistance to several cephalosporin ana-
logues. Moreover, TEM-12 is the intermediate
between TEM-1 and TEM-10, with only one of the
two amino-acid substitutions present in TEM-10
which is a clear ESBL (Table 1) [13,22].
My preference, based on increased activity and
the ability to confer resistance, is to include TEM-
12 and variants like it as ESBLs. This was
supported by a show of hands at the conference.
Any other solution demands drawing a border at
some arbitrary level of increased activity, such as
the 10% ﬁgure used to deﬁne group 2be, and this
would cause further anomalies. For example, an
Table 1. Hydrolytic proﬁles, sequences and resistance conferred for selected b-lactamases belonging to the TEM family
Amino-acid at position Relative Vmax
MICs (mg ⁄L) for Escherichia coli
K-12 transconjugants
39 104 164 238 240 Benzylpenicillin Cefotaxime Ceftazidime Ampicillin Cefotaxime Ceftazidime
None 2 0.06 0.06–0.12
TEM-1 Gln Glu Arg Glu Glu 100 0.01 <0.01 >128 0.06–0.12 0.12–0.25
TEM-3 Lys Lys Arg Ser Glu 100 170 8.3 >128 64–256 32–128
TEM-10 Gln Glu Ser Glu Lys 100 2.1 90 >128 0.25–4 32–256
TEM-12 Gln Glu Ser Glu Glu 100 0.75 0.10 >128 0.12 4–8
Data are from [13,22], and also http://www.lahey.org/studies
Bold font indicates changed amino acids
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enzyme hydrolysing ceftazidime at 11% of the
rate for benzylpenicillin, but hydrolysing cefotax-
ime at 1%, would count as an ESBL, whereas one
hydrolysing both cephalosporins at 9% of the rate
for penicillin would fail to count.
EXTENDED-SPECTRUM MUTANTS
OUTSIDE MOLECULAR CLASS A
All the b-lactamase variants so far discussed
belong to molecular class A and, to begin with,
it was thought that ESBL-type activity could
evolve only in this family. During the early
1990s, however, Danel and others worked exten-
sively on class D b-lactamases, noting again that
point mutation could extend the ability to confer
resistance. Thus, OXA-15 is a mutant of OXA-2
[23], while OXA-11, -14, -16 and -17 are variants of
OXA-10 (PSE-2) [24–27]. In each case, the mutants
confer wider resistance to oxyimino-cephalospo-
rins than their parent types (Table 2). These early
OXA ESBLs were found in Pseudomonas aeruginosa
from Turkey, although further examples, more
recently, have been found in P. aeruginosa from
France [28,29].
Although strains and transconjugants with
OXA variants have increased resistance to one
or more oxyimino-cephalosporins (Table 2), the
extracted enzymes show little convincing increase
in cephalosporinase activity, except perhaps that
OXA-11 has a raised kcat ⁄Km for ceftazidime [27].
Moreover, and like OXA enzymes in general, they
are poorly inhibited by clavulanate. At one level,
these considerations argue against counting the
OXA mutants as ESBLs; nevertheless, and as with
the borderline TEM types, their extended ability
to confer resistance argues for their inclusion, and
this view was supported by the majority of the
conference audience.
The lack of a clear relationship between the
ability to confer resistance and the kinetics of the
extracted enzymes probably reﬂects the notori-
ous difﬁculty of measuring the kinetics of OXA
enzymes in general. Both OXA-2 and -10 and
their variants exist as dimers at high concentra-
tion, as in the bacterial periplasm, but tend to
dissociate into less active monomers when
diluted into the assay mixture [30]. The result,
in standard assays, is a hydrolysis ‘rate’ that
declines more rapidly than can be explained by
substrate depletion, and which may have little
relevance to whatever cephalosporin inactivation T
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rate the dimeric enzyme achieves in the peri-
plasm.
Class C (AmpC) enzymes further complicate
the deﬁnition of ESBLs. Typical AmpC enzymes,
which belong to functional group 1, as clavula-
nate-resistant cephalosporinases, confer resis-
tance to most oxyimino-cephalosporins if
hyperproduced as a result of mutational dere-
pression in, e.g., Enterobacter spp. [5,31], or if they
become plasmid-encoded and constitutive [32,33].
This ability reﬂects high afﬁnity (1ow Km values)
for oxyimino-cephalosporins, which confers cata-
lytic efﬁciency despite low kcat values [34,35].
By convention, AmpC enzymes are counted
separately from ESBLs, but a taxonomic problem
arises with AmpC mutants that have increased
activity against cefepime and cefpirome, fourth-
generation cephalosporins that have acceptable, if
incomplete, stability to classic AmpC types. Such
mutants have been seen among clinical Serratia
and Enterobacter isolates [36,37], and have been
obtained in laboratory selection experiments
[38,39]; their increased activity may reﬂect greater
afﬁnity (lowered Km) or an increased kcat
(Table 3). So far, such mutants have arisen from
inherent chromosomal AmpC types, but they
could equally evolve from the plasmidic AmpC
types that are increasingly circulating in Klebsiella
spp. and E. coli. Should such mutants be included
as ESBLs, on the basis of having an extended
spectrum as compared with their parent AmpC
types? I would say ‘yes’, although a show of
hands at the conference indicated that this was
the minority view.
CARBAPENEM-HYDROLYSING
b -LACTAMASES
b-Lactamases able to confer resistance to carba-
penems are now recognised in classes A (e.g.,
IMI, KPC, NMC and SME), B (e.g., VIM, IMP,
GIM, and SPM) and D (e.g., OXA-23-like, OXA-
24-like, OXA-49, OXA-51-like and OXA-58)
[40,41]. Most workers, myself included, count
these separately from ESBLs, even though (i) most
can also hydrolyse oxyimino-cephalosporins, and
(ii) some of the class A types (which fall into
Bush’s group 2f) are inhibited, albeit rather
weakly, by clavulanate [42]. The pragmatic rea-
sons for separating carbapenemases from ESBLs
are surely: (i) that carbapenemase activity is not a
feature of ESBLs in general; and (ii) that, since
carbapenems are often the last-resort b-lactams,
any enzyme that confers resistance to them must
be seen as a further threat, over and above that
associated with an ESBL.
A problem does, however, arise with the GES
family, where substitution of Gly170 with aspara-
gine (GES-2) or serine (GES-3 and 4) confers the
ability to cause low-level imipenem resistance,
particularly in an impermeable host such as
P. aeruginosa [43,44]. For GES-2, the increased
activity reﬂects a reduced Km and, hence, greater
afﬁnity, not a raised kcat (Table 4) [44]. Such
enzymes clearly meet the criterion of having an
extended spectrum as compared with their parent
type; moreover, they conform with the deﬁnitions
for functional group 2be, as clavulanate-inhibited
broad-spectrumenzymes that are able tohydrolyse
Table 3. ‘Extended-spectrum’ activity in chromosomal AmpC enzymes from Serratia marcescens, increasing the ability to
confer cefepime resistance
Kinetics of parent
enzyme
Kinetics of mutant
enzyme, with
four-amino-acid
deletion in H-10
helix
MICs for Escherichia coli recipient
and transconjugants
kcat
a ( ⁄ s) Km (lM) kcat ( ⁄ s) Km (lM) R
Transconjugant
with control
enzyme
Transconjugant
with mutant
enzyme
Benzylpenicillin 35 9 50 10 – – –
Cefotaxime 6 7 5 2 <0.06 8 16
Ceftazidime 5 >1000 270 20 <0.06 16 512
Cefepime 80 >1000 50 6 <0.06 2 512
Data are from [36].
akcat is a more fundamental measure of Vmax, cited in other tables, being the maximum number of substrate molecules that
one enzyme molecule can transform per unit time.
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oxyimino-cephalosporins at 10% or more of the
rate for benzylpenicillin … but they also stray into
the realm of carbapenemases!
TOWARDS A PRAGMATIC
DEFINITION
The term ‘ESBL’ was coined when fewer b-lacta-
mases were known, and served well for the TEM
and SHV mutants, both: (i) because they had high
kcat rates for oxyimino-cephalosporins; and (ii)
because they had an extended spectrum as com-
pared with their parent types. As the catalogue of
b-lactamases has grown, enzymes have been
called ESBLs on the basis of meeting either one of
these criteria, or owing to the ability to confer
resistance rather than to cause rapid hydrolysis.
Several enzymes now included as ESBLs—notably
the OXA variants—lack obvious cephalosporinase
activity in standard assays, despite an ability to
confer resistance, and are resistant to clavulanate.
If it is accepted that ESBLs are now a broad
church and should remain so, then a deﬁnition that
would still serve would be ‘any b-lactamase,’
generally acquired rather than inherent to a spe-
cies, that is either able to confer resistance to
oxyimino-cephalosporins (but not carbapenems),
or that has an increased ability to do so, as
compared with classic members of its genetic
family. To be meaningful, such a deﬁnition
demands that the ESBL class is also speciﬁed, as
with ‘TEMESBL’, ‘OXAESBL’ or ‘CTX-MESBL’, or
‘extended-spectrum AmpC’. This would resolve
most confusion, although the carbapenem-hydro-
lysing GES types still present a problem.
The alternative would be to restrict the term
‘ESBL’ to those enzymes meeting the criteria for
functional group 2be, meaning CTX-M, VEB,
SHV, most TEM types and a few obscure types.
This, however, would exclude the ‘borderline’
TEM ESBLs and would demand the coining of a
new term for the OXA ESBLs and those AmpC
mutants with increased activity against cefepime.
This surely would be a less satisfactory solution
and—inappropriately—would exclude many
of the enzymes included by presenters at this
meeting.
Finally, it should be said that the great majority
of the ESBLs encountered clinically belong to the
TEM, SHV and CTX-M families. These are what
are routinely sought in clinical laboratory ESBL
tests, and it is their spread—and particularly that
of the CTX-M types—which is causing public
health concern. The OXA, GES and AmpC types
that so complicate the deﬁnition remain extremely
rare.
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